Patents by Inventor David A. Scott

David A. Scott has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12268739
    Abstract: Provided herein are Toll-like receptor 2 (TLR2) agonists for use in enhancing human immune response and/or as adjuvants in vaccines. The TLR2 agonists include thiophenes, imidazoles, or phenyl-containing compounds, which may be compounds of Formulae (I), (II), (III), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions thereof. The compounds described herein are used as enhancers of an immune response (e.g., innate and/or adaptive immune response), and are useful in treating and/or preventing a disease, as adjuvants in a vaccine for the disease. (e.g., proliferative disease, inflammatory disease, autoimmune disease, infectious disease, or chronic disease). Also provided in the present disclosure are pharmaceutical compositions, kits, methods, and uses including or using a compound described herein.
    Type: Grant
    Filed: July 26, 2019
    Date of Patent: April 8, 2025
    Assignees: Children's Medical Center Corporation, Dana-Farber Cancer Institute, Inc.
    Inventors: David J. Dowling, Ofer Levy, Francesco Borriello, David A. Scott, Spencer E. Brightman
  • Patent number: 12195770
    Abstract: The disclosure describes novel systems, methods, and compositions for the manipulation of nucleic acids in a targeted fashion. The disclosure describes non-naturally occurring, engineered CRISPR systems, components, and methods for targeted modification of nucleic acids such as DNA. Each system includes one or more protein components and one or more nucleic acid components that together target nucleic acids.
    Type: Grant
    Filed: March 14, 2019
    Date of Patent: January 14, 2025
    Assignee: Arbor Biotechnologies, Inc.
    Inventors: Elise Keston-Smith, David A. Scott, David R. Cheng, Winston X. Yan, Pratyusha Hunnewell, Jason Carte
  • Publication number: 20240409908
    Abstract: The disclosure describes novel systems, methods, and compositions for the manipulation of nucleic acids in a targeted fashion. The disclosure describes non-naturally occurring, engineered CRISPR systems, components, and methods for targeted modification of DNA, RNA, and protein substrates. Each system includes one or more protein components and one or more nucleic acid components that together target DNA, RNA, or protein substrates.
    Type: Application
    Filed: June 13, 2024
    Publication date: December 12, 2024
    Applicant: Arbor Biotechnologies, Inc.
    Inventors: David A. Scott, David R. Cheng, Winston X. Yan
  • Patent number: 12161649
    Abstract: The application relates to compounds, or pharmaceutically acceptable salts, hydrates, solvates, or stereoisomers thereof, which modulate the activity of EGFR, a pharmaceutical composition comprising said compounds, and methods of treating or preventing a disease in which EGFR plays a role.
    Type: Grant
    Filed: June 21, 2019
    Date of Patent: December 10, 2024
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Nathanael S. Gray, Jaebong Jang, Dries De Clercq, David A. Scott
  • Publication number: 20240301446
    Abstract: The disclosure describes Cas12i2 fusion proteins, methods, and compositions for the manipulation of nucleic acids in a targeted fashion. The disclosure describes non-naturally occurring, engineered Cas12i2 fusion proteins, components, and methods for targeted modification of nucleic acids. Each system, includes one or more protein components and one or more nucleic acid components that together target nucleic acids.
    Type: Application
    Filed: January 20, 2022
    Publication date: September 12, 2024
    Inventors: Brendan Jay Hilbert, Noah Michael Jakimo, David A. Scott, Colin Alexander McGaw, Jason Michael Carte
  • Patent number: 12054754
    Abstract: The disclosure describes novel systems, methods, and compositions for the manipulation of nucleic acids in a targeted fashion. The disclosure describes non-naturally occurring, engineered CRISPR systems, components, and methods for targeted modification of DNA, RNA, and protein substrates. Each system includes one or more protein components and one or more nucleic acid components that together target DNA, RNA, or protein substrates.
    Type: Grant
    Filed: November 2, 2018
    Date of Patent: August 6, 2024
    Assignee: Arbor Biotechnologies, Inc.
    Inventors: David A. Scott, David R. Cheng, Winston X. Yan
  • Patent number: 11976308
    Abstract: The disclosure describes novel systems, methods, and compositions for the manipulation of nucleic acids in a targeted fashion. The disclosure describes non-naturally occurring, engineered CRISPR systems, components, and methods for targeted modification of nucleic acids. Each system includes one or more protein components and one or more nucleic acid components that together target nucleic acids.
    Type: Grant
    Filed: December 28, 2022
    Date of Patent: May 7, 2024
    Assignee: ARBOR BIOTECHNOLOGIES, INC.
    Inventors: David A. Scott, David R. Cheng, Winston X. Yan, Tia M. Ditommaso
  • Patent number: 11945816
    Abstract: The application relates to a compound having Formula X: which modulates the activity of HER2 and/or a mutant thereof, and/or EGFR and/or a mutant thereof, a pharmaceutical composition comprising the compound, and a method of treating or preventing a disease in which HER2 and/or a mutant thereof, and/or EGFR and/or a mutant thereof, plays a role.
    Type: Grant
    Filed: October 20, 2021
    Date of Patent: April 2, 2024
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: John M. Hatcher, Nathanael S. Gray, Jaebong Jang, Dries De Clercq, Pasi Janne, Jamie A. Saxon, Michael Eck, David A. Scott, Alyssa Verano
  • Publication number: 20240101990
    Abstract: The disclosure describes novel systems, methods, and compositions for the manipulation of nucleic acids in a targeted fashion. The disclosure describes non-naturally occurring, engineered CRISPR systems, components, and methods for targeted modification of nucleic acids. Each system includes one or more protein components and one or more nucleic acid components that together target nucleic acids.
    Type: Application
    Filed: September 12, 2023
    Publication date: March 28, 2024
    Inventors: David A. Scott, David R. Cheng, Winston X. Yan, Tia M. DiTommaso
  • Publication number: 20240102007
    Abstract: A gene editing system comprising: (a) a Type V CRISPR nuclease polypeptide or a first nucleic acid encoding the Type V CRISPR nuclease polypeptide; (b) a reverse transcriptase (RT) polypeptide or a second nucleic acid encoding the RT polypeptide; (c) a guide RNA (gRNA) or a third nucleic acid encoding the gRNA, wherein the gRNA comprises one or more binding sites recognizable by the Type V CRISPR nuclease (CRISPR nuclease binding sites) and a spacer sequence specific to a target sequence within a genomic site of interest, the target sequence being adjacent to a protospacer adjacent motif (PAM); and (d) a reverse transcription donor RNA (RT donor RNA) or a fourth nucleic acid encoding the RT donor RNA, wherein the RT donor RNA comprises a primer binding site (PBS) and a template sequence.
    Type: Application
    Filed: June 1, 2022
    Publication date: March 28, 2024
    Applicant: Arbor Biotechnologies, Inc.
    Inventors: David A. Scott, Noah Michael Jakimo, Pratyusha Hunnewell, Fu-Kai Hsieh
  • Publication number: 20240093228
    Abstract: The present invention relates to nucleases or nucleic acids encoding the nucleases, RNA guides or nucleic acids encoding the RNA guides, processes for characterizing the nucleases and/or RNA guides, compositions comprising the nucleases and/or RNA guides, and kits and/or methods for preparing and/or using the nucleases and/or RNA guides.
    Type: Application
    Filed: January 21, 2022
    Publication date: March 21, 2024
    Inventors: David A. SCOTT, David R. CHENG, Winston X. YAN, Tia M. DITOMMASO
  • Patent number: 11912992
    Abstract: The disclosure describes novel systems, methods, and compositions for the manipulation of nucleic acids in a targeted fashion. The disclosure describes non-naturally occurring, engineered CRISPR systems, components, and methods for targeted modification of nucleic acids such as DNA. Each system includes one or more protein components and one or more nucleic acid components that together target nucleic acids.
    Type: Grant
    Filed: December 9, 2022
    Date of Patent: February 27, 2024
    Assignee: ARBOR BIOTECHNOLOGIES, INC.
    Inventors: Shaorong Chong, Winston X Yan, David A. Scott, David R. Cheng, Pratyusha Hunnewell
  • Publication number: 20240011031
    Abstract: The present invention relates nucleases, processes for characterizing the nucleases, compositions comprising the nucleases, and methods of using the nucleases.
    Type: Application
    Filed: August 17, 2021
    Publication date: January 11, 2024
    Applicant: Arbor Biotechnologies, Inc.
    Inventors: David A. Scott, David R. Cheng, Winston X. Yan, Tia M. Ditommaso
  • Publication number: 20230407281
    Abstract: The disclosure describes novel systems, methods, and compositions for the manipulation of nucleic acids in a targeted fashion. The disclosure describes non-naturally occurring, engineered Type III-E CRISPR-Cas systems, components, and methods for targeted modification of DNA, RNA, and protein substrates. Each system includes one or more protein components and one or more nucleic acid components that together target DNA, RNA, or protein substrates.
    Type: Application
    Filed: April 24, 2023
    Publication date: December 21, 2023
    Inventors: David R. Cheng, David A. Scott, Winston X. Yan
  • Publication number: 20230374926
    Abstract: An internal combustion engine includes a cylinder head with an exhaust manifold configured to supply exhaust gas through a main exhaust outlet to a main exhaust aftertreatment system having a main catalytic converter, a bypass passage in fluid communication with the exhaust manifold via a bypass port, a bypass catalytic converter disposed within the bypass passage, and a dual-acting valve assembly configured to move between a first position that seals the bypass port, and a second position that seals the main exhaust outlet. During cold start, long idle, and/or low main catalytic converter temperature conditions, the dual-active valve assembly is moved to the second position to direct exhaust flow through the bypass passage and the bypass catalytic converter to reduce emissions.
    Type: Application
    Filed: April 28, 2023
    Publication date: November 23, 2023
    Inventors: Jeff Brand, Michael P. Schmidt, David A. Scott, Philip J. Insalaco
  • Patent number: 11795442
    Abstract: The disclosure describes novel systems, methods, and compositions for the manipulation of nucleic acids in a targeted fashion. The disclosure describes non-naturally occurring, engineered CRISPR systems, components, and methods for targeted modification of nucleic acids. Each system includes one or more protein components and one or more nucleic acid components that together target nucleic acids.
    Type: Grant
    Filed: August 17, 2022
    Date of Patent: October 24, 2023
    Assignee: ARBOR BIOTECHNOLOGIES, INC.
    Inventors: David A. Scott, David R. Cheng, Winston X. Yan, Tia M. DiTommaso
  • Publication number: 20230332119
    Abstract: The present invention relates to variant Cas12i2 polypeptides, methods of producing the variant Cas12i2 polypeptides, processes for characterizing the variant Cas12i2 polypeptides, cells comprising the variant Cas12i2 polypeptides, and methods of using the variant Cas12i2 polypeptides. The invention further relates to complexes comprising the variant Cas12i2 polypeptides, methods of producing the complexes, processes for characterizing the complexes, cells comprising the complexes, and methods of using the complexes.
    Type: Application
    Filed: March 31, 2021
    Publication date: October 19, 2023
    Inventors: Shaorong CHONG, Brendan Jay HILBERT, Quinton Norman WESSELLS, Noah Michael JAKIMO, Roy ZIBLAT, Jason Michael CARTE, Tia Marie DITOMMASO, Jeffrey Raymond HASWELL, Anthony James GARRITY, Colin Alexander MCGAW, David A. SCOTT, Derek Michael CERCHIONE
  • Publication number: 20230287456
    Abstract: The present invention relates to compositions comprising a Cas12i polypeptide, a deaminase polypeptide, and an RNA guide, processes for characterizing the compositions, cells comprising the compositions, Cas12i fusion proteins, Cas12i complexes, and methods of using the compositions.
    Type: Application
    Filed: September 9, 2022
    Publication date: September 14, 2023
    Inventors: Noah Michael Jakimo, Pratyusha Hunnewell, Brendan Jay Hilbert, David A. Scott
  • Patent number: 11730810
    Abstract: Provided herein are imidazopyrimidine compounds, such as compounds of Formula (I), for use in enhancing human immune response and/or as adjuvants in vaccines.
    Type: Grant
    Filed: November 14, 2018
    Date of Patent: August 22, 2023
    Assignees: Children's Medical Center Corporation, Dana-Farber Cancer Institute, Inc.
    Inventors: Ofer Levy, David J. Dowling, Francesco Borriello, David A. Scott, Spencer E. Brightman, Frederic Feru
  • Publication number: 20230242891
    Abstract: The disclosure describes novel systems, methods, and compositions for the manipulation of nucleic acids in a targeted fashion. The disclosure describes non-naturally occurring, engineered CRISPR systems, components, and methods for targeted modification of nucleic acids such as DNA. Each system includes one or more protein components and one or more nucleic acid components that together target nucleic acids.
    Type: Application
    Filed: March 14, 2019
    Publication date: August 3, 2023
    Inventors: Elise Keston-Smith, David A. Scott, David R. Cheng, Winston X. Yan, Pratyusha Hunnewell, Jason Carte